NCT03335553View on ClinicalTrials.gov

A Study of Experimental Medication BMS-986235 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

November 15, 2017

Primary Completion Date

July 2, 2021

Study Completion Date

July 2, 2021

Conditions
Mediators of Inflammation
Interventions
DRUG

BMS-986235

Specified dose on specified days

OTHER

Placebo

Specified dose on specified days

Trial Locations (2)

84107

PRA Health Sciences, Salt Lake City

92801

Anaheim Clinical Trials, Anaheim

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY